HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency.
Related News Articles
Headline
There have been 2,318 confirmed measles cases in the U.S. so far this year, the most in the country since 1991, according to the latest data from the…
Headline
The AHA’s Living Learning Network, in partnership with the Centers for Disease Control and Prevention, July 22 released “Rural Sepsis Care in Action: Real-…
Headline
A Centers for Disease Control and Prevention report released July 16 found that wastewater surveillance failed to detect an internationally circulating measles…
Headline
The Centers for Disease Control and Prevention July 14 released an advisory on the growing cyclosporiasis cases across the U.S. The advisory said that the…
Headline
The Centers for Disease Control and Prevention has reported 843 cases of cyclosporiasis across 31 states, with 86 people hospitalized. State health departments…
Headline
President Trump signed an executive order May 29 that directs the Centers for Disease Control and Prevention and the Advisory Committee on Immunization…